Patients might describe generalized pruritus, widespread areas of tenderness or hyperesthesia, or skin reactivity in areas distant from injection sites
To assess the amount of variability explained by covariate factors, a base model was investigated, including only covariates for the effects of drug product strength on the absorption rate constant
Since then, several GLP-1s for obesity have been approved for new indications such as secondary cardiovascular risk reduction (Wegovy), sleep apnea (Zepbound) and metabolic dysfunction-associated steatohepatitis or MASH (Wegovy)
Dikshit P, Chatterjee M, Goswami A, Mishra A, Jana NR (2006) Aspirin induces apoptosis through the inhibition of proteasome function
For all-cause mortality and RFS in patients with obesity, the 5-year survival probability was 97.4% and 96% with GLP-1 RA use, and 93.2% and 91.3% with non-use, respectively
Yes, it is formulated to suit all skin types